Introduction
============

Dengue is an acute viral infection associated with thrombocytopenia, which is of great public health concern in India. Dengue fever (DF) is a severe, flu-like illness that affects all age groups including infants, young children, and adults. DF is caused by flavivirus transmitted mainly by *Aedes aegypti* and also by *Aedes albopictus* mosquitoes.[@b1-phmt-10-005] In India, *A. aegypti* is the main vector in most urban areas; however, *A. albopictus* is also implicated in many states.

Characteristic manifestations of DF are continuous high fever, headache, retro-orbital pain, myalgia, arthralgia, hemorrhagic tendency in the form of petechiae or epistaxis, thrombocytopenia, and increase in hematocrit values.[@b1-phmt-10-005]--[@b3-phmt-10-005] After the incubation period of 4--10 days, there is a rapid onset of symptoms and typically there are three phases in DF: febrile phase, critical phase, and recovery phase.

Dengue is one of the rapidly spreading mosquito-borne viral diseases worldwide. It is a major public health concern throughout the tropical and subtropical regions of the world. In the present decade, the incidence has increased in both urban and rural settings. WHO estimates that there may be 50--100 million dengue infections and half a million dengue hemorrhagic fever (DHF) worldwide every year, with an average case fatality rate of around 5%.[@b4-phmt-10-005],[@b5-phmt-10-005] A total of 3.6 billion people are at the risk of infection across 120 dengue-endemic countries. More than 70% of those at risk live in the Asia Pacific region, making this region an epicenter of dengue activity.[@b6-phmt-10-005] Increasing burden of dengue has been a matter of serious concern worldwide. Dengue is widespread in India, and outbursts occur every year. The first epidemic of clinical dengue-like fever was recorded in Vellore of Tamil Nadu, and the first virologically proved epidemic of DF occurred in Kolkata and Eastern Coast of India in 1963--1964.[@b1-phmt-10-005],[@b7-phmt-10-005]--[@b9-phmt-10-005] Most of the cases are being reported in the monsoon and post-monsoon seasons.[@b1-phmt-10-005],[@b10-phmt-10-005] The first major widespread epidemics of DHF/dengue shock Syndrome(DSS) occurred in India in 1996, involving areas around Lucknow and Delhi and then it spread to all over the country.[@b1-phmt-10-005] DF diagnosis is done by detecting anti-DV IgM antibodies or by NS-1 antigen in patients' serum depending upon day of illness.[@b11-phmt-10-005] A single tube nested PCR is used for detection and serotyping of dengue virus.[@b12-phmt-10-005] Dengue virus isolation in tissue culture cells and its sequencing are also being carried out for research purpose.[@b13-phmt-10-005] There is no specific treatment for dengue; early detection and intensive supportive care are the most essential aspects of management. Thrombocytopenia usually occurs in the critical phase, and if left unattended or untreated it can lead to increased morbidity and mortality. As of now, there is no approved vaccine or allopathic medicine for the definitive management of DF. Few anecdotal reports have highlighted the ayurvedic or herbal preparations for treating thrombocytopenia in patients with dengue.

Focus on *Carica papaya* leaf extract (CPLE): a novel therapeutic option
------------------------------------------------------------------------

*C. papaya* is a member of the Caricaceae family and belongs to dicotyledonous, polygamous, and diploid species.[@b14-phmt-10-005] *C. papaya* leaves are being used in ayurvedic medicine since many years. Its use as an anti-inflammatory agent, for its wound-healing properties,[@b15-phmt-10-005] antitumor as well as immune modulatory effects,[@b16-phmt-10-005] and as an antioxidant[@b17-phmt-10-005] is being studied. Safety studies for chronic, subacute, and acute toxicities were conducted on CPLE and demonstrated to be safe for human consumption based on the OECD guidelines.[@b18-phmt-10-005] Some of the genes have shown to influence platelet production, namely, arachidonate 12-lipoxygenase (ALOX 12) and platelet-activating factor receptor (PTAFR). An upsurge in the activity of these genes is necessary for platelet production and activation. The ALOX 12 gene is intensely expressed in megakaryocytes, and it has shown to be accountable for the 12-hydroxyeicosatetraenoic acid (12-HETE) production of platelets in patients treated with CPLE extract.[@b19-phmt-10-005] On megakaryocytes, PTAFR gene is expressed, which indicates that it might be a precursor for platelet production. Clinical evidence shows that *C. papaya* extract enhances the PTFAR activity around 13-fold and the ALOX 12 activity 15-fold, which is responsible for increased platelet production.[@b20-phmt-10-005]--[@b22-phmt-10-005] With this established mechanism of action, in few countries the leaf extract of *C. papaya* has been used in DF disease.[@b21-phmt-10-005],[@b22-phmt-10-005] However, there is limited literature available regarding the therapeutic options for the management of DF-induced thrombocytopenia in the pediatric age group. Hence, this study was conducted to assess the efficacy and safety of CPLE, for thrombocytopenia associated with DF in pediatric subjects.

Materials and methods
=====================

An open-label, randomized, prospective study was conducted in Vijaynagar Institute of Medical Sciences Hospital in pediatric subjects with dengue (NS1 antigen positive) associated with thrombocytopenia or DHF grades I and II.

A total of 294 subjects were randomized into intervention and control groups of 147 each. Two were dropped out from the intervention group since they withdrew from the study and got admitted into some different hospitals. Seven were dropped out from the control group. So, a total of 285 subjects were evaluated (n=145 in the interventional group and n=140 in the control group).

Both the groups were managed with the standard management. In addition, the intervention group received CPLE (Caripill) syrup formulation according to the age groups: children aged between 1 and 5 years received 275 mg three times daily and children above 5 years received 550 mg three times for 5 days. The control group received standard treatment only. All the subjects were followed up for platelet count, red blood cell (RBC) count, and white blood cell (WBC) count daily for 5 days.

The inclusion criteria to participate in this study are as follows. Males and females between 1and 12 years of age, who are confirmed to have DF or DHF grades I and II by NS1 antigen test and thrombocytopenia with a platelet count of 30,000--100,000/μL, were included in the study. Subjects with a baseline alanine transaminase level of not more than three times of the upper limit of the normal range and are willing to give informed consent to participate in the study were included in the study.

Subjects with DHF grades III and IV, platelet count less than 30,000/mL, subjects who have received blood or blood product transfusion during the current illness, and subjects with idiopathic thrombocytopenia purpura (ITP), leukemia, and hemophilia were excluded from the study. Also, subjects who have a serum ALT level three times higher than the upper limit of the normal range (\>165 U/L) and impaired renal function with serum creatinine \>1.5 mg/dL (males) and \>1.4 mg/dL (females) were excluded from the trial. Subjects who participated in another trial with an investigational drug within 1 month prior to this trial, hypersensitivity to any of the components of the formulation, and the presence of any other condition that leads the investigator to conclude that the subjects are inappropriate for inclusion in this clinical study were excluded from the study.

The primary outcome measured was a mean increase in the platelet counts from the baseline levels to the end of therapy (Day 5); secondary outcomes were change in the RBC and WBC counts from the baseline levels till the end of therapy (Day 5) and tolerability and safety assessment based on adverse effects as mentioned by the parents/guardians and evaluated by the investigator.

Written informed consent was obtained from their parents or guardians. Institutional ethics committee (Vijayanagara Institute of Medical Sciences, Bellary) approval was obtained before initiation of the study, and the trial has been registered in the clinical trial registry, India (CTRI registration number: CTRI/2018/03/012792). The CONSORT flow diagram is shown in [Figure 1](#f1-phmt-10-005){ref-type="fig"}.

The platelets of both the groups were monitored every day along with RBC and WBC counts. All the subjects were monitored for any adverse events throughout the study period.

Independent *t*-test was used to analyze the mean platelet, RBC, and WBC counts between the groups. Paired *t*-test was used to compare the mean values of the parameters in the intervention group before and after treatment (ie, baseline and at the end of 5 days). Significance levels were set at *P*-value ≤0.05.

Results
=======

This study was carried out in 285 pediatric subjects diagnosed with dengue with thrombocytopenia; of whom, 145 subjects (77 males and 68 females) were included in the interventional group and 140 subjects (66 males and 74 females) in the control group ([Figure 1](#f1-phmt-10-005){ref-type="fig"}).

Mean age in the intervention group was 7.43±3.61 and the control group was 8.07±2.92. The demographic characteristics (mean age, gender, height, and weight) are mentioned in [Table 1](#t1-phmt-10-005){ref-type="table"}.

In both groups, subjects presented with symptoms of dengue, ie, high fever, headache, retro-orbital pain rash, and joint pain, and diagnosis was confirmed with NS1 antigen test. Mean increase in the platelet count was considered as the primary outcome, and mean increase in RBC and WBC counts was considered as the secondary outcome.

Results indicate that there is consistent increase in the platelet count in the intervention group and the control group. In the intervention group, there is statistically significant increase compared to the control group. The increase in the platelet count in the intervention group was statistically significant on Day 3 (mean platelet count=89,739.31±29,973.62, *P*=0.030), Day 4 (mean platelet count=120,788.96±36,404.03, *P*=0.019), and Day 5 (mean platelet count=168,922.75±49,706.55 *P*=0.023; [Figure 2](#f2-phmt-10-005){ref-type="fig"}).

As a part of secondary outcome assessment, mean increase in RBC count and WBC count was analyzed in both intervention and control groups. It has been observed in the study that there is an increase in the RBC and WBC counts in both groups; however, the mean increase was statistically not significant in the control group. In the intervention group, it has been observed that the mean increase in RBC count was found to be statistically significant on Day 5 (mean RBC count=3.89±0.45×10^6^/µL, *P*=0.03), and the mean increase in WBC count was statistically significant on Day 3 (mean WBC count =4.74±0.46×10^3^/µL, *P*=0.038), Day 4 (mean WBC count =5.42±0.56×10^3^/µL, *P*=0.047), and Day 5 (mean WBC count =6.65±0.65×10^3^/µL, *P*=0.008). The graphs of mean change in the RBC count and WBC count are shown in [Figures 3](#f3-phmt-10-005){ref-type="fig"} and [4](#f4-phmt-10-005){ref-type="fig"}, respectively.

All 294 subjects were evaluated for safety and tolerability. Two subjects complained of nausea in the intervention group. Overall, Caripill syrup was well tolerated in all other subjects.

Discussion
==========

Thrombocytopenia is a well-known complication of the DF.[@b23-phmt-10-005]

Thrombocytopenia is often characterized by bruising, purpura in forearms, pinpoint hemorrhages, epistaxis, and bleeding gums. Important causes of thrombocytopenia in DF are bone marrow suppression in early stage, disseminated intravascular coagulation, peripheral sequestration of platelets, destruction of platelets (antiplatelet antibodies). Severe thrombocytopenia is associated with complications such as DHF and DSS, and if untreated leads to morbidity and mortality.[@b23-phmt-10-005],[@b24-phmt-10-005]

DF affects all the age groups and especially the pediatric age group is at high risk.[@b25-phmt-10-005] Infants with DF typically have high fever that usually lasts 2--7 days as seen in older children. However, compared to older children, gastrointestinal symptoms such as vomiting, diarrhea, respiratory tract symptoms (nasal congestion, runny nose, cough, and dyspnea), and febrile convulsions are more common in infants with dengue.[@b25-phmt-10-005]

Clinical features and laboratory findings of infants infected with dengue become more prominent during this critical phase. Petechiae, mucosal membrane bleeding (eg, nose and gums), and gastrointestinal bleeding may occur. Leukopenia and thrombocytopenia are often observed in this phase. Progression of the disease course of dengue in infants is the same as that of children during the recovery phase.[@b25-phmt-10-005]

This study is one of the first studies to evaluate the CPLE in pediatric patients with DF. Studies conducted in adult patients with dengue have shown that CPLE had significant increase (*P*\<0.01) in the platelet count over the therapy duration, in DF patients, confirming that CPLE accelerates the increase in platelet count compared to the control group.[@b26-phmt-10-005]

Furthermore, study conducted by many active components of *C. papaya* extract inhibits immune-mediated platelet destruction, bone marrow suppression, and stabilizes the membrane of infected cells in dengue. Papaya leaf extract raised the platelet count by Day 3 with decreased requirement of platelet transfusion. The drug did not produce any major side effects.[@b27-phmt-10-005]

In this study, similar results were observed in pediatric patients with dengue. CPLE (Caripill) syrup increased the platelet count significantly compared to the control group (*P*\<0.05). In the intervention group, platelet count increased from Day 3 onward: platelet count on Day 3 (mean platelet count =89,739.31, *P*=0.030), Day 4 (mean platelet count =120,788.96, *P*=0.019), and Day 5 (mean platelet count=168,922.75 *P*=0.023).

Caripill syrup may have positive impact on RBC and WBC counts in pediatric subjects with DF based on the study results. Caripill syrup was well tolerated by all the patients. No major adverse events were reported.

Conclusion
==========

In this open-label, randomized prospective study, CPLE (Caripill) syrup is shown to increase the mean platelet count in thrombocytopenia associated with DF in pediatric subjects. The syrup was well tolerated, and it can add to the therapeutic armamentarium in the management of DF as supportive therapy.

The Caripill samples for the clinical trial were provided by Micro Labs Ltd.
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###### 

Demographic characteristics

                   Intervention group (n=145)   Control group (n=140)
  ---------------- ---------------------------- -----------------------
                                                
  Age in years     7.43±3.61                    8.07±2.92
  Gender                                        
   Male, n (%)     77 (53.1)                    66 (47.14)
   Female, n (%)   68 (46.89)                   74 (52.85)
  Height in cm     121.16±37.92                 126.82±28.23
  Weight in kg     23.71±7.12                   25.2±5.86

**Note:** Data shown as mean ± SD or n (%).
